FDA Officially Ranks Condoms for Anal and Vaginal Use as 'Class II' Gadgets
Published Date: 5/8/2026
Rule
Summary
The FDA is officially classifying external condoms for anal or vaginal sex as Class II devices, meaning they have special safety rules but aren’t super strict. This change helps make sure condoms are safe and effective while making it easier for new, innovative products to reach you. The new rules took effect on May 8, 2026, and could speed up how quickly better condoms hit the market without extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Condoms Reclassified to Class II
The FDA has officially classified external condoms for anal or vaginal intercourse as Class II (special controls). FDA says this classification provides a reasonable assurance of safety and effectiveness and will enhance patient access to innovative condom products by reducing regulatory burdens; the order is effective May 8, 2026 (classification applicable February 23, 2022).
New Testing and Labeling Rules for Makers
Manufacturers must meet new special controls: clinical acute failure modes studies for total and individual failure rates; non‑clinical performance testing including mechanical/material integrity and (for non‑latex materials) viral penetration testing; biocompatibility evaluation; shelf‑life performance and package integrity data; and specific labeling elements. These controls are codified at 21 CFR 884.5305 and apply to devices classified as external condoms for anal or vaginal intercourse.
Premarket 510(k) Notification Required
FDA states that external condoms for anal or vaginal intercourse are subject to premarket notification under section 510(k) of the FD&C Act and that it has not determined these devices should be exempt under section 510(m). Sponsors must therefore submit a 510(k) to market these devices unless FDA later exempts them.
Labels Must Give Clear Safety & Effectiveness Info
Required labeling must include (if indicated for vaginal intercourse) a contraceptive effectiveness table comparing typical and perfect use pregnancy rates; statements on lubricant compatibility; statements of adverse events (including infection, pregnancy, tissue reaction, mechanical injury, improper use); an expiration date; STI protection specifics; a statement that risks are not eliminated; a warning about failure during anal intercourse if adequate lubricant is not used; a warning that the device is single‑use; and a precaution about allergy risk.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17498, Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The Food and Drug Administration (FDA or Agency) is extending the effective date of the notice published in the Federal Register on May 27, 2026, entitled "Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661" (91 FR 31462) (the "May 2026 Notice"), as previously extended by the notice published in the Federal Register on June 26, 2026 (91 FR 38717) (the "June 2026 Notice"), by an additional 41 days. The effective date of the May 2026 Notice, which was previously extended to September 24, 2026, is hereby further extended to November 4, 2026. This further extension is necessary to allow FDA sufficient time to consider issues raised by interested parties.
2026-17380, International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
The FDA is asking the public to share their thoughts on eight drugs that might get new international rules to control their use and abuse. This affects doctors, patients, and drug makers because it could change how these drugs are used medically or restricted worldwide. Comments are open until September 3, 2026, so jump in and have your say before the deadline!
2026-17401, Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CABAZITAXEL (cabazitaxel) solution (injection), 60 milligrams (mg)/6 milliliters (mL) (10 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for Cabazitaxel (cabazitaxel) solution (injection), 60 mg/6 mL (10 mg/mL), if all other legal and regulatory requirements are met.
Previous / Next Documents
Previous: 2026-09148, Implementation of the Administrative False Claims Act; Correction
The Federal Labor Relations Authority fixed a few wording mistakes in its new rules for the Administrative False Claims Act, which helps catch and stop false claims against the government. These corrections make the rules clearer and officially take effect on May 26, 2026. If you work with government claims or legal procedures, these updates keep things running smoothly without changing any costs or deadlines.
Next: 2026-09155, Changes to National Firearms Act Tax Remittance Provisions
Starting June 10, 2026, the ATF is updating its rules to match new laws that lower the tax rates on certain National Firearms Act (NFA) guns. This means folks who deal with these firearms will pay less tax when registering or transferring them. The changes keep the rules clear, fair, and up-to-date with the latest law.